Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis

被引:16
作者
Han, Ziqin [1 ,2 ]
Chen, Qiuying [1 ,2 ]
Zhang, Lu [1 ,2 ]
Mo, Xiaokai [1 ]
You, Jingjing [1 ,2 ]
Chen, Luyan [1 ,2 ]
Fang, Jin [1 ]
Wang, Fei [1 ]
Jin, Zhe [1 ,2 ]
Zhang, Shuixing [1 ]
Zhang, Bin [1 ]
机构
[1] Jinan Univ, Affiliated Hosp 1, Dept Radiol, 613 Huangpu West Rd, Guangzhou, Guangdong, Peoples R China
[2] Jinan Univ, Grad Coll, Guangzhou, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Glioma; Isocitrate dehydrogenase; Mutation; Magnetic resonance imaging; PHASE-III TRIAL; ANAPLASTIC OLIGODENDROGLIOMA; 1P/19Q STATUS; CLASSIFICATION;
D O I
10.1007/s00330-022-08607-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To reveal a radiogenomic correlation between the presence of the T2-fluid-attenuated inversion recovery resection (T2-FLAIR) mismatch sign on MR images and isocitrate dehydrogenase (IDH) mutation status in adult patients with lower-grade gliomas (LGGs). Methods A web-based systemic search for eligible literature up to April 13, 2021, was conducted on PubMed, Embase, and the Cochrane Library databases by two independent reviewers. This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. We included studies evaluating the accuracy of the T2-FLAIR mismatch sign in diagnosing the IDH mutation in adult patients with LGGs. The T2-FLAIR mismatch sign was defined as a T2-hyperintense lesion that is hypointense on FLAIR except for a hyperintense rim. Results Fourteen studies (n = 1986) were finally identified. The mean age of patients in the included studies ranged from 38.5 to 56 years. The pooled area under the curve (AUC), sensitivity, and specificity were obtained for each molecular profile: IDHmut-Codel: 0.46 (95% confidence interval [CI]: 0.42-0.50), 1% (95%CI: 0-7%), and 69% (95%CI: 62-75%), respectively; IDHmut-Noncodel: 0.75 (95%CI: 0.71-0.79), 42% (95%CI: 34-50%), and 99% (95%CI: 96-100%), respectively; IDH-Mutation regardless of 1p/19q codeletion status: 0.77 (95%CI: 0.73-0.80), 29% (95%CI: 21-40%), and 99% (95%CI: 92-100%), respectively. Conclusions The T2-FLAIR mismatch sign was an insensitive but highly specific marker for IDHmut-Noncodel and IDH-Mutation LGGs, whereas it was not a useful marker for IDHmut-Codel LGGs. The findings might identify the T2-FLAIR mismatch sign as a non-invasive imaging biomarker for the selection of patients with IDH-mutant LGGs.
引用
收藏
页码:5339 / 5352
页数:14
相关论文
共 30 条
[1]   Automated apparent diffusion coefficient analysis for genotype prediction in lower grade glioma: association with the T2-FLAIR mismatch sign [J].
Aliotta, Eric ;
Dutta, Sunil W. ;
Feng, Xue ;
Tustison, Nicholas J. ;
Batchala, Prem P. ;
Schiff, David ;
Lopes, M. Beatriz ;
Jain, Rajan ;
Druzgal, T. Jason ;
Mukherjee, Sugoto ;
Patel, Sohil H. .
JOURNAL OF NEURO-ONCOLOGY, 2020, 149 (02) :325-335
[2]   Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas [J].
Batchala, P. P. ;
Muttikkal, T. J. E. ;
Donahue, J. H. ;
Patrie, J. T. ;
Schiff, D. ;
Fadul, C. E. ;
Mrachek, E. K. ;
Lopes, M-B. ;
Jain, R. ;
Patel, S. H. .
AMERICAN JOURNAL OF NEURORADIOLOGY, 2019, 40 (03) :426-432
[3]   The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study [J].
Broen, Martinus P. G. ;
Smits, Marion ;
Wijnenga, Maarten M. J. ;
Dubbink, Hendrikus J. ;
Anten, Monique H. M. E. ;
Schijns, Olaf E. M. G. ;
Beckervordersandforth, Jan ;
Postma, Alida A. ;
van den Bent, Martin J. .
NEURO-ONCOLOGY, 2018, 20 (10) :1393-1399
[4]   Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 [J].
Cairncross, Gregory ;
Berkey, Brian ;
Shaw, Edward ;
Jenkins, Robert ;
Scheithauer, Bernd ;
Brachman, David ;
Buckner, Jan ;
Fink, Karen ;
Souhami, Luis ;
Laperierre, Normand ;
Mehta, Minesh ;
Curran, Walter .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2707-2714
[5]   Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402 [J].
Cairncross, Gregory ;
Wang, Meihua ;
Shaw, Edward ;
Jenkins, Robert ;
Brachman, David ;
Buckner, Jan ;
Fink, Karen ;
Souhami, Luis ;
Laperriere, Normand ;
Curran, Walter ;
Mehta, Minesh .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (03) :337-343
[6]   The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study [J].
Corell, Alba ;
Vega, Sandra Ferreyra ;
Hoefling, Nickoleta ;
Carstam, Louise ;
Smits, Anja ;
Bontell, Thomas Olsson ;
Bjorkman-Burtscher, Isabella M. ;
Caren, Helena ;
Jakola, Asgeir Store .
BMC CANCER, 2020, 20 (01)
[7]   The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed [J].
Deeks, JJ ;
Macaskill, P ;
Irwig, L .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2005, 58 (09) :882-893
[8]   Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas [J].
Deguchi, Shoichi ;
Oishi, Takuma ;
Mitsuya, Koichi ;
Kakuda, Yuko ;
Endo, Masahiro ;
Sugino, Takashi ;
Hayashi, Nakamasa .
SCIENTIFIC REPORTS, 2020, 10 (01)
[9]   Conducting systematic reviews of diagnostic studies: Didactic guidelines [J].
Devillé W.L. ;
Buntinx F. ;
Bouter L.M. ;
Montori V.M. ;
De Vet H.C.W. ;
Van Der Windt D.A.W.M. ;
Bezemer P.D. .
BMC Medical Research Methodology, 2 (1) :1-13
[10]   T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology [J].
Foltyn, Martha ;
Taborda, Karen Natalia Nieto ;
Neuberger, Ulf ;
Brugnara, Gianluca ;
Reinhardt, Annekathrin ;
Stichel, Damian ;
Heiland, Sabine ;
Herold-Mende, Christel ;
Unterberg, Andreas ;
Debus, Juergen ;
Von Deimling, Andreas ;
Wick, Wolfgang ;
Bendszus, Martin ;
Kickingereder, Philipp .
NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)